Go Deep
Bicara Therapeutics Inc.
Bicara Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,373 | -5.6 | 2.45 | 0.00 | 1,651.35 |
| Oct 2026 | 20,373 | -5.6 | 2.45 | 0.00 | 1,646.39 |
| Oct 2026 | 20,308 | -5.7 | 2.49 | 0.00 | 1,673.21 |
| Oct 2026 | 20,503 | -5.4 | 2.37 | 0.00 | 1,589.32 |
| Oct 2026 | 20,343 | -5.7 | 2.47 | 0.00 | 1,656.44 |
| Oct 2026 | 20,138 | -6.0 | 2.59 | 0.00 | 1,739.88 |
| Oct 2026 | 20,241 | -5.8 | 2.53 | 0.00 | 1,693.97 |
| Oct 2026 | 20,310 | -5.7 | 2.49 | 0.00 | 1,662.22 |
| Oct 2026 | 20,436 | -5.5 | 2.41 | 0.00 | 1,617.93 |
Bicara Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -55,436,000.0 | -56,211,000.0 | -37,386,000.0 | -36,330,000.0 |
| EPS | -0.8 | -0.9 | -0.7 | -0.7 |
Bicara Therapeutics Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -137,950,000.0 | -67,995,000.0 | -51,985,000.0 | -37,845,000.0 |
| EPS | -2.5 | -4.0 | -1.5 | -2.5 |
Bicara Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 430,994,000.0 | 509,996,000.0 | 233,982,000.0 | 6,703,000.0 |
| Total Liabilities | 29,542,000.0 | 18,121,000.0 | 382,751,000.0 | 105,506,000.0 |
| Total Equity | 401,452,000.0 | 491,875,000.0 | -148,769,000.0 | -98,803,000.0 |
Owes vs Owns
Bicara Therapeutics Inc. owed $0.08 for every $1 it owned in Jun 2026, down from $15.7 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.08× | 0.07× | 0.04× | 1.64× | 15.7× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Bicara Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 96.2%Other assets 3.3%
How it's funded — Dec 2025
Payables 1.8%Other liabilities 4.6%Shareholders' equity 93.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 414.8 | 489.7 | 230.4 | 4.2 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 2.0 | 0.8 | 0.8 | 0.6 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 14.2 | 19.4 | 2.7 | 1.9 |
| Liabilities & equity | ||||
| Short-term debt | 1.1 | 0.6 | 0.3 | 0.0 |
| Long-term debt | 0.6 | 0.1 | 0.4 | 0.0 |
| Payables | 7.8 | 4.5 | 3.2 | 5.1 |
| Other liabilities | 20.0 | 12.9 | 378.9 | 100.4 |
| Shareholders' equity | 401.5 | 491.9 | -148.8 | -98.8 |
| Net tangible assets | 401.5 | 491.9 | -148.8 | -98.8 |
Bicara Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -106,834,000.0 | -74,751,000.0 | -45,628,000.0 | -32,076,000.0 |
| Investing Activities | -318,453,000.0 | -9,000.0 | -586,000.0 | -192,000.0 |
| Financing Activities | 32,261,000.0 | 334,031,000.0 | 272,496,000.0 | 31,695,000.0 |